A Phase 4 interventional study of idebenone 30 mg for 14 days and idebenone 30 mg for 3 months in Post Stroke Epilepsy, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Xiangya Hospital of Central South University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.
Among the 101 studies in Epilepsy with a site in China, this one is the 2nd largest by planned enrollment of the 64 interventional ones that give a count, is one of 8 that started in 2023, is one of 5 in phase 4, reaches primary completion later than 8 of the 40 other live ones, and was the 70th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in China
Ages 18–65
Shanghai UniXell Biotechnology Co., Ltd · Sites in China
Ages 18–75
Xuanwu Hospital, Beijing · Sites in China
Ages 18–60
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Sites in China
Ages 18+ · Women only · Healthy volunteers
Xijing Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 6 · Phase 3 23 · Phase 4 5
First in 2006; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,700 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 141 across the 64 interventional studies, 234 across the 37 observational. Of the 37 that completed or were terminated, 22 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 101 have an industry lead sponsor. The 10 most frequent:
Xiangya Hospital of Central South University is the lead sponsor of 177 studies on the registry; 80 are open to participants now.
Xiangya Hospital of Central South University has 2 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
14 of the studies in Epilepsy with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT07095933Xuanwu Hospital, BeijingThe Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy | 2026-12-01 |
| NCT03822741Children's Hospital of Fudan UniversityEtiology and Treatment of Neonatal Seizure | 2026-12-30 |
| NCT04917939Second Affiliated Hospital, School of Medicine, Zhejiang UniversityGene Expression Changes of Brain Tissue in Human Temporal Lobe Epilepsy With Hippocampal Sclerosis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 101 studies in Epilepsy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
According to the random number table, all patients were divided into short-term treatment group, long-term treatment group and non-intervention stroke control group according to the proportion of (1:1:1) epilepsy disease modifier idebenone. Patients in the short-term treatment group will take idebenone for a total course of 14 days (acute period) after stroke, and patients in the long-term treatment group will take idebenone for a total course of 3 months after stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
Drug: idebenone 30 mg for 14 days
The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
Drug: idebenone 30 mg for 3 months
The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
The proportion of patients with epilepsy after stroke
Count the number of people with post-stroke epilepsy
Time frame: At the time of enrollment
The proportion of patients with epilepsy after stroke
Count the number of people with post-stroke epilepsy
Time frame: 24 weeks after enrollment
The proportion of patients with epilepsy after stroke
Count the number of people with post-stroke epilepsy
Time frame: 48 weeks after enrollment
National Institutes of Health Stroke Scale (NIHSS)
The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients
Time frame: At the time of enrollment
National Institutes of Health Stroke Scale (NIHSS)
The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients
Time frame: 24 weeks after enrollment
National Institutes of Health Stroke Scale (NIHSS)
The minimum value is 0, the maximum value is 24, the higher score indicates the more severe neurological impairment in stroke patients
Time frame: 48 weeks after enrollment
Hamilton Anxiety Scale (HAMA)
The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety
Time frame: At the time of enrollment
Hamilton Anxiety Scale (HAMA)
The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety
Time frame: 24 weeks after enrollment
Hamilton Anxiety Scale (HAMA)
The minimum value is 0, the maximum value is 56, the higher score indicates a great likelihood of anxiety
Time frame: 48 weeks after enrollment
Hamilton Depression Scale (HAMD)
The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression
Time frame: At the time of enrollment
Hamilton Depression Scale (HAMD)
The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression
Time frame: 24 weeks after enrollment
Hamilton Depression Scale (HAMD)
The minimum value is 0, the maximum value is 77, the higher score indicates a great likelihood of depression
Time frame: 48 weeks after enrollment
Pittsburgh sleep quality index (PSQI)
The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality
Time frame: At the time of enrollment
Pittsburgh sleep quality index (PSQI)
The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality
Time frame: 24 weeks after enrollment
Pittsburgh sleep quality index (PSQI)
The minimum value is 0, the maximum value is 21, the higher score indicates poorer sleep quality
Time frame: 48 weeks after enrollment
Stroke specific quality of life scale (SS-QOL)
The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life
Time frame: At the time of enrollment
Stroke specific quality of life scale (SS-QOL)
The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life
Time frame: 24 weeks after enrollment
Stroke specific quality of life scale (SS-QOL)
The minimum value is 38, the maximum value is 190, the higher score indicates better quality of life
Time frame: 48 weeks after enrollment
Started Jul 2023 (actual). Primary completion is estimated for Dec 2025, 29 months after the start.
Of 33 non-industry phase 4 interventional studies under Epilepsy, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 29 months is above that.
Counting every sponsor, half of 43 studies reached it within 25 months; a quarter within 12 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idebenone
Xiangya Hospital of Central South University →